BAN0805 is an antibody against alpha-synuclein and a drug candidate for the treatment of Parkinson’s disease.
The goal is to develop a disease modifying treatment that stops or slows down disease progression. The project is based on research from Uppsala University in Sweden.
A collaboration with AbbVie started in 2016 regarding the continued development of BioArctic’s Parkinson program, focusing on BAN0805 and additional antibodies, for the application to the U.S. Food and Drug Administration (FDA) for the initiation of a clinical study of BAN0805 in the U.S., an IND.
In November 2018, AbbVie announced that they will exercise their option to license BioArctic’s alpha-synuclein antibody portfolio, pending clearance under the U.S. antitrust legislation.